Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Net Cash Flow (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Net Cash Flow data on record, last reported at $1.6 million in Q3 2025.

  • For Q3 2025, Net Cash Flow rose 191.03% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.7 million, up 127.21%, while the annual FY2024 figure was -$4.3 million, 25.54% up from the prior year.
  • Net Cash Flow reached $1.6 million in Q3 2025 per CYCN's latest filing, up from -$633000.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $25.1 million in Q2 2021 and bottomed at -$13.0 million in Q1 2021.
  • Average Net Cash Flow over 5 years is -$3.1 million, with a median of -$1.9 million recorded in 2024.
  • The widest YoY moves for Net Cash Flow: up 336.5% in 2021, down 185.52% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$8.5 million in 2021, then grew by 17.72% to -$7.0 million in 2022, then skyrocketed by 78.08% to -$1.5 million in 2023, then soared by 123.36% to $360000.0 in 2024, then surged by 333.89% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $1.6 million in Q3 2025, -$633000.0 in Q2 2025, and $407000.0 in Q1 2025.